Together these results suggest the effectiveness of the combined use of taxanes and therapies directed against HER2 in ERα+/PR+/HER2+ cells, since these drugs may target karyotypically distinct subpopulations within the same tumor (intratumoral CH)60. The gene discussed is ERBB2; the disease is neoplasm.